NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Jackie Schumacher to lead Global Regulatory Affairs. In this role, Ms. Schumacher will have responsibility for Rallybio’s global regulatory strategy and operations across the portfolio, including the Company’s lead product candidate, RLYB211, which is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
“We continue to build our world-class team and are very pleased to welcome Jackie to the Company,” said Steve Uden, MD, co-founder of Rallybio. “As we prepare to advance RLYB211 into the clinic, Jackie’s vast global regulatory and development experience will be important for our success. Her expertise further enables Rallybio to achieve its mission of bringing life-transforming therapies to patients in need.”
Ms. Schumacher has more than 30 years of diverse experience in global regulatory affairs, development, commercialization and portfolio management from initial clinical investigation through registration. Prior to joining Rallybio, Jackie served as Vice President of Regulatory and Quality at Lyndra Therapeutics where she was responsible for regulatory strategy and operations and for overseeing the Company’s global GxP quality strategy and Quality Management System. Previously, she spent more than two decades in pharmaceutical sciences within Pfizer, starting as an analytical chemist followed by a long tenure within the Chemistry, Manufacturing, and Controls (CMC) regulatory organization. During her time at Pfizer, she developed and led successful global CMC registration strategies for new small molecules, product enhancements, and combination products, held regulatory leadership positions within the nascent Established Products Sterile Injectables organization and was responsible for helping to optimize the value of the company’s 600+ established molecule portfolio. She is currently on the board of directors for Women in the Enterprise of Science and Technology, a non-profit dedicated to the advancement of women in science, technology, and engineering.
“I’m thrilled to join a team with such an unwavering focus on patients and look forward to exploring opportunities for partnering with global regulatory agencies to deliver transformative treatment options to patients suffering from severe and rare diseases,” said Ms. Schumacher.
Ms. Schumacher received a Bachelor of Arts in chemistry and classical studies from Hamilton College.
About Rallybio
Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.
